• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session

    9/8/22 12:15:08 PM ET
    $AEO
    $AGS
    $ALBO
    $ALLG
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary
    Miscellaneous manufacturing industries
    Consumer Discretionary
    Get the next $AEO alert in real time by email

    Gainers

    • ShiftPixy, Inc. (NASDAQ:PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.
    • Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) surged 64% to $29.35 after the FDA Advisory Committee voted that available evidence of effectiveness is sufficient to support approval of AMX0035 for the treatment of ALS. Citigroup and SVB Leerink raised their price targets.
    • Benitec Biopharma Inc. (NASDAQ:BNTC) shares rose 58% to $0.9346. The company, last week, filed its annual report on Form 10-K for the quarter ended June 30, 2022, with the U.S. Securities and Exchange Commission.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) rose 39.4% to $1.21 after declining 11% on Wednesday. Rubius Therapeutics, last month, posted a Q2 loss of $0.49 per share.
    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) gained 22.2% to $0.2733.
    • Nutex Health, Inc. (NASDAQ:NUTX) gained 21.5% to $3.85. Nutex Health recently posted a Q2 loss of $0.03 per share.
    • Asana, Inc. (NYSE:ASAN) shares gained 21% to $23.03 after the company reported better-than-expected results for its second quarter and issued a strong sales guidance. RBC Capital and Citigroup raised their price targets on the stock.
    • Relay Therapeutics, Inc. (NASDAQ:RLAY) surged 19.9% to $30.40. Relay Therapeutics announced efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients with a FGFR2-fusion or rearrangement FGFR inhibitor-naïve cholangiocarcinoma: ReFocus trial.
    • Allego N.V. (NYSE:ALLG) gained 17.6% to $4.63. Allego recently announced first half financial results and 2022 revenue expectations.
    • LifeStance Health Group, Inc. (NASDAQ:LFST) rose 17.6% to $8.95. LifeStance Health named Ken Burdick as CEO and Chairman.
    • Terns Pharmaceuticals, Inc. (NASDAQ:TERN) jumped 15.8% to $4.40.
    • AeroVironment, Inc. (NASDAQ:AVAV) gained 15.3% to $102.20 after reporting upbeat quarterly sales.
    • Eve Holding, Inc. (NYSE:EVEX) rose 14.8% to $7.07. United reported a $15 million investment in Eve Air Mobility and a conditional purchase agreement for 200 four-seat electric aircraft plus 200 options.
    • Cazoo Group Ltd (NYSE:CZOO) surged 14.7% to $0.70. The company announced it will wind down operations in mainland Europe to focus on core UK market
    • Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) rose 14.6% to $23.90. Rhythm Pharmaceuticals announced new employment inducement grants. Goldman Sachs maintained Rhythm Pharmaceuticals with a Buy and raised the price target from $28 to $31.
    • Forge Global Holdings, Inc. (NYSE:FRGE) rose 14.4% to $4.45.
    • Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) gained 14.1% to $680.56 after the company announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.
    • Phreesia, Inc. (NYSE:PHR) rose 13.6% to $27.19 after the company reported better-than-expected Q2 sales results and raised the low-end of its FY23 sales guidance.
    • Intapp, Inc. (NASDAQ:INTA) gained 12.4% to $16.52 after the company reported better-than-expected Q4 results and issued guidance above estimates.
    • First High-School Education Group Co., Ltd. (NYSE:FHS) rose 11.4% to $0.7150.
    • Albireo Pharma, Inc. (NASDAQ:ALBO) surged 11% to $18.50. Guggenheim initiated coverage on Albireo Pharma with a Buy rating and announced a price target of $55.
    • Mullen Automotive, Inc. (NASDAQ:MULN) gained 10.7% to $0.7449 after the company announced it has acquired a 60% controlling interest in Bollinger Motors for $148.2 million in cash and stock.
    • Lyft, Inc. (NASDAQ:LYFT) gained 10.5% to $16.25 amid vague rumors from a questionable source mentioning the company.
    • Revance Therapeutics, Inc. (NASDAQ:RVNC) rose 9.4% to $22.78 after the company announced FDA approval of DAXXIFY for injection for temporary improvement of moderate to severe frown lines.
    • Snap Inc. (NYSE:SNAP) rose 7.3% to $12.29 on continued strength after a recent internal memo obtained by The Verge suggested the company is aiming to reach $6 billion in revenue and 450 million users by next year.
    • Heliogen, Inc. (NYSE:HLGN) rose 7% to $2.3650.
    • GameStop Corp. (NYSE:GME) rose 7% to $25.72 after the company reported better-than-expected earnings for its second quarter and also announced a partnership with cryptocurrency exchange FTX to bring more customers to the digital asset space.
    • Zillow Group, Inc. (NASDAQ:ZG) gained 6.9% to $37.80 after Jefferies maintained a Buy rating on the stock and raised its price target from $48 to $50.

     

    Losers

    • Great Panther Mining Limited (NYSE:GPL) shares dropped 21.4% to $0.2542. The company recently announced it has determined to file a notice of intention to make a proposal under the Bankruptcy and Insolvency Act, which will provide credit protection.
    • Troika Media Group, Inc. (NASDAQ:TRKA) fell 18.3% to $0.5310 after declining around 6% on Wednesday.
    • Erasca, Inc. (NASDAQ:ERAS) declined 18.1% to $7.70. Erasca announced preliminary Phase 1/1b monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in BRAF-driven and RAS/MAPK-altered solid tumors.
    • PlayAGS, Inc. (NYSE:AGS) shares fell 17.4% to $6.29.
    • Biophytis S.A. (NASDAQ:BPTS) declined 16.2% to $0.9301. Biophytis recently announced top-line results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.
    • Ensysce Biosciences, Inc. (NASDAQ:ENSC) declined 15.8% to $0.3475.
    • Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) dipped 15.2% to $1.68.
    • Bilibili Inc. (NASDAQ:BILI) fell 13.8% to $20.37 following Q2 results.
    • Tandy Leather Factory Inc. (NASDAQ:TLF) fell 13% to $5.35 following uplisting of its stock.
    • Graphex Group Limited (NASDAQ:GRFX) dropped 12.7% to $1.64. The company recently provided a business update and highlighted 2022 milestones.
    • MasterCraft Boat Holdings, Inc. (NASDAQ:MCFT) fell 12.3% to $20.84. The company posted upbeat quarterly earnings, but issued weak FY23 forecast. MasterCraft Boat also sold its NauticStar business to Iconic Marine Group.
    • Mercer International Inc. (NASDAQ:MERC) dipped 10.8% to $14.32.
    • Genenta Science S.p.A. (NASDAQ:GNTA) fell 10.7% to $4.75.
    • Chembio Diagnostics, Inc. (NASDAQ:CEMI) shares fell 10.6% to $0.56. Chembio Diagnostics filed for potential stock offering.
    • Dave & Buster's Entertainment, Inc. (NASDAQ:PLAY) dropped 10.2% to $39.47. While the company reported better-than-expected Q2 results, operating income dropped from 2021 levels.
    • Skillsoft Corp. (NYSE:SKIL) fell 10% to $2.42 after the company posted downbeat quarterly sales and authorized a $30 million share buyback.
    • The Lovesac Company (NASDAQ:LOVE) dropped 8.3% to $27.40 following Q2 results.
    • HyreCar Inc. (NASDAQ:HYRE) fell 8.2% to $1.2575. HyreCar shares gained around 8% on Wednesday after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist Partners.
    • American Eagle Outfitters, Inc. (NYSE:AEO) shares fell 7.8% to $10.68 after the company reported worse-than-expected Q2 EPS results.
    • McCormick & Company, Incorporated (NYSE:MKC) fell 7.7% to $78.47. McCormick said it expects third-quarter FY22 sales to increase about 3% year-on-year and 6% in constant currency.
    • Grid Dynamics Holdings, Inc. (NASDAQ:GDYN) fell 7.5% to $18.31 after the company priced its common stock offering of about 5.71 million shares at $17.50 per share.
    • Wayfair Inc. (NYSE:W) fell 6.3% to $47.50 after the company reported a proposed offering of $600 million convertible senior notes.
    Get the next $AEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEO
    $AGS
    $ALBO
    $ALLG

    CompanyDatePrice TargetRatingAnalyst
    Snap Inc.
    $SNAP
    4/14/2026$7.00 → $6.00Hold
    Canaccord Genuity
    McCormick & Company Incorporated
    $MKC
    4/14/2026Neutral
    BTIG Research
    Asana Inc.
    $ASAN
    4/14/2026$7.00Overweight → Neutral
    Piper Sandler
    Bilibili Inc.
    $BILI
    4/13/2026$31.00Equal-Weight → Overweight
    Morgan Stanley
    Phreesia Inc.
    $PHR
    4/1/2026Mkt Outperform → Mkt Perform
    Citizens
    Asana Inc.
    $ASAN
    4/1/2026$7.00Underperform → Sector Perform
    RBC Capital Mkts
    Regeneron Pharmaceuticals Inc.
    $REGN
    3/31/2026$875.00Overweight
    Piper Sandler
    Phreesia Inc.
    $PHR
    3/31/2026$10.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $AEO
    $AGS
    $ALBO
    $ALLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity reiterated coverage on Snap with a new price target

    Canaccord Genuity reiterated coverage of Snap with a rating of Hold and set a new price target of $6.00 from $7.00 previously

    4/14/26 1:08:30 PM ET
    $SNAP
    Computer Software: Programming Data Processing
    Technology

    BTIG Research initiated coverage on McCormick

    BTIG Research initiated coverage of McCormick with a rating of Neutral

    4/14/26 8:24:09 AM ET
    $MKC
    Packaged Foods
    Consumer Staples

    Asana downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Asana from Overweight to Neutral and set a new price target of $7.00

    4/14/26 8:14:22 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    $AEO
    $AGS
    $ALBO
    $ALLG
    SEC Filings

    View All

    SEC Form DEF 14A filed by Regeneron Pharmaceuticals Inc.

    DEF 14A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    4/24/26 4:02:55 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Regeneron Pharmaceuticals Inc.

    DEFA14A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    4/24/26 4:04:21 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 14D9/A filed by Terns Pharmaceuticals Inc.

    SC 14D9/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    4/24/26 8:11:05 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEO
    $AGS
    $ALBO
    $ALLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer-Healthcare Montgomery Pamela W. bought $7,021 worth of shares (79 units at $88.87), increasing direct ownership by 3% to 2,758 units (SEC Form 4)

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/16/26 3:02:43 PM ET
    $NUTX
    Real Estate

    Large owner Kellogg Peter R bought $236,600 worth of shares (70,000 units at $3.38) (SEC Form 4)

    4 - MERCER INTERNATIONAL INC. (0001333274) (Issuer)

    3/10/26 1:18:16 PM ET
    $MERC
    Paper
    Basic Materials

    Director Laberge Alice bought $1,900 worth of shares (1,000 units at $1.90) (SEC Form 4)

    4 - MERCER INTERNATIONAL INC. (0001333274) (Issuer)

    2/27/26 2:42:29 PM ET
    $MERC
    Paper
    Basic Materials

    $AEO
    $AGS
    $ALBO
    $ALLG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    March 22, 2024 - FDA Roundup: March 22, 2024

    For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Pemgarda is

    3/22/24 5:02:42 PM ET
    $SNAP
    $SRAX
    Computer Software: Programming Data Processing
    Technology
    Advertising
    Consumer Discretionary

    November 9, 2023 - FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder

    For Immediate Release: November 09, 2023 Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains

    11/9/23 2:30:20 PM ET
    $SRAX
    $SNAP
    Advertising
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology

    $AEO
    $AGS
    $ALBO
    $ALLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Reed Michael Lee

    4 - Nutex Health Inc. (0001479681) (Issuer)

    4/24/26 2:35:38 PM ET
    $NUTX
    Real Estate

    SEC Form 4 filed by Director Saunders Scott J

    4 - Nutex Health Inc. (0001479681) (Issuer)

    4/24/26 2:32:08 PM ET
    $NUTX
    Real Estate

    SEC Form 4 filed by Director Jaumot Frank E

    4 - Nutex Health Inc. (0001479681) (Issuer)

    4/24/26 2:27:51 PM ET
    $NUTX
    Real Estate

    $AEO
    $AGS
    $ALBO
    $ALLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Merck's pending acquisition of Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN) expired at 11:59 p.m., Eastern Time, on April 23, 2026. As previously announced on April 7, 2026, Merck commenced, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns, for $53.00 net in cash for each share of Terns common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable tax withholding. The ex

    4/24/26 6:45:00 AM ET
    $MRK
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mercer International Inc. Announces Conference Call for First Quarter 2026 Results

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Mercer International (NASDAQ:MERC) will release its first quarter results for the period ending March 31, 2026 on Thursday, April 30, 2026, after the close of the market. Juan Carlos Bueno, President and Chief Executive Officer and Richard Short, Chief Financial Officer and Secretary, will be hosting a conference call on Friday, May 1, 2026, at 10:00 am ET to discuss the results. The conference call will be available to interested parties live over the Internet through a webcast by clicking on or copying and pasting the following link into their web browser: https://edge.media-server.com/mmc/p/ha9u4g4a A link to the webcast is also available o

    4/23/26 4:30:00 PM ET
    $MERC
    Paper
    Basic Materials

    Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

    Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha), its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid prices based on prices in other developed countries; prices for future medicines in the U.S. will be aligned with prices set in that defined group of other countries Praluent® (alirocumab), an important cardiovascular medicine, will be available for direct patient purchase through TrumpRx.gov Regeneron will continue its large investment in domestic R&D and manufacturing capacity TARRYTOWN, N.Y., April 23, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced an

    4/23/26 3:46:16 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEO
    $AGS
    $ALBO
    $ALLG
    Leadership Updates

    Live Leadership Updates

    View All

    AV Appoints Sean Woodward as Chief Financial Officer

      AeroVironment, Inc. ("AV") (NASDAQ:AVAV), a global defense technology leader, today announced the appointment of Sean T. Woodward as Executive Vice President and Chief Financial Officer, effective May 1, 2026. Woodward succeeds Kevin McDonnell, who will be stepping down from the role, as announced earlier this year. McDonnell will remain with the Company in an advisory role through July 2026 to help ensure a smooth transition of responsibilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260412005321/en/Sean Woodward is a seasoned finance leader with more than 22 years of experience in defense technology, including at A

    4/13/26 8:00:00 AM ET
    $AVAV
    Aerospace
    Industrials

    AV Appoints Dr. Robert Smith as Chief Operating Officer

    Defense Veteran to Strengthen Operational Execution as AV Scales Manufacturing and Supply Chain Capabilities AeroVironment, Inc. ("AV") (NASDAQ:AVAV), a global defense technology leader, today announced the appointment of Dr. Robert (Rob) Smith as Executive Vice President and Chief Operating Officer, effective April 13, 2026. In this role, Dr. Smith will oversee the Company's Autonomous Systems (AxS) and Space, Cyber and Directed Energy (SCDE) business units, as well as the Company's global operations and manufacturing footprint. His appointment reflects AV's continued focus on scaling manufacturing to meet rising customer demand, strengthening operational execution and enhancing capabi

    4/9/26 9:10:00 AM ET
    $AVAV
    Aerospace
    Industrials

    Rhythm Pharmaceuticals Announces Changes to Board of Directors

    -- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced changes to its Board of Directors, including the appointment of Kim Popovits and the departure of Ed Mathers. "We are thrilled to welcome Kim to our Board of Directors," said David Meeker, M.D., Chairman, President and Chief Executive Officer of Rhythm. "Kim brings decades of leadership experience across biotechnology, diagnostics and commercial innovation, with a proven track record

    4/3/26 9:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEO
    $AGS
    $ALBO
    $ALLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Wheeler Real Estate Investment Trust Inc.

    SC 13D/A - Wheeler Real Estate Investment Trust, Inc. (0001527541) (Subject)

    12/9/24 5:54:19 PM ET
    $WHLR
    Real Estate Investment Trusts
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Wheeler Real Estate Investment Trust Inc.

    SC 13G/A - Wheeler Real Estate Investment Trust, Inc. (0001527541) (Subject)

    12/5/24 5:28:41 PM ET
    $WHLR
    Real Estate Investment Trusts
    Real Estate

    $AEO
    $AGS
    $ALBO
    $ALLG
    Financials

    Live finance-specific insights

    View All

    Mercer International Inc. Announces Conference Call for First Quarter 2026 Results

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Mercer International (NASDAQ:MERC) will release its first quarter results for the period ending March 31, 2026 on Thursday, April 30, 2026, after the close of the market. Juan Carlos Bueno, President and Chief Executive Officer and Richard Short, Chief Financial Officer and Secretary, will be hosting a conference call on Friday, May 1, 2026, at 10:00 am ET to discuss the results. The conference call will be available to interested parties live over the Internet through a webcast by clicking on or copying and pasting the following link into their web browser: https://edge.media-server.com/mmc/p/ha9u4g4a A link to the webcast is also available o

    4/23/26 4:30:00 PM ET
    $MERC
    Paper
    Basic Materials

    Lyft Expands in London with Gett UK Acquisition

    Key takeaways: Lyft has agreed to acquire Gett's United Kingdom business with close expected in the coming weeks, subject to customary closing conditions. Gett is one of London's leading black cab apps with strong enterprise business-to-business (B2B) relationships, and brings together the majority of Greater London's registered black cab drivers and will nearly double the number of rides on the Lyft platform in London. With Gett, Lyft is expanding its coverage of London's full ground transport ecosystem. This advances Lyft's sustainable global growth strategy, while expanding "out" in more locations and "up" into more high-value segments. Lyft (NASDAQ:LYFT) has agreed to acq

    4/23/26 8:48:00 AM ET
    $LYFT
    Real Estate

    Nutex Health Schedules 2026 First Quarter Financial Results Release and Conference Call

    HOUSTON, April 22, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Form 10-Q for the first fiscal quarter ended March 31, 2026, on Thursday, April 30, 2026 after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, May 1, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and provide a b

    4/22/26 4:15:00 PM ET
    $NUTX
    Real Estate